Trial · NCT01664182
Results by group104
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 104
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Observed Response Rate | Arm I (Trebananib Monotherapy) | 0 | 95% Confidence Interval 0 to 20 | percentage of patients responding | |
| Observed Response Rate | Arm II (Trebananib and Anti-VEGF Therapy) | 11 | 95% Confidence Interval 1 to 35 | percentage of patients responding | |
| Tumor Response | Arm I (Trebananib Monotherapy) | Partial Response | 0 | Participants | |
| Tumor Response | Arm II (Trebananib and Anti-VEGF Therapy) | Partial Response | 2 | Participants | |
| Tumor Response | Arm I (Trebananib Monotherapy) | Stable Disease | 5 | Participants | |
| Tumor Response | Arm II (Trebananib and Anti-VEGF Therapy) | Stable Disease | 8 | Participants | |
| Tumor Response | Arm I (Trebananib Monotherapy) | Progressive Disease | 11 | Participants | |
| Tumor Response | Arm II (Trebananib and Anti-VEGF Therapy) | Progressive Disease | 6 | Participants | |
| Tumor Response | Arm I (Trebananib Monotherapy) | Not Evaluable | 1 | Participants | |
| Tumor Response | Arm II (Trebananib and Anti-VEGF Therapy) | Not Evaluable | 2 | Participants | |
| Progression Free Survival (PFS) | Arm I (Trebananib Monotherapy) | 2.7 | 95% Confidence Interval 2.3 to 4.7 | months | |
| Progression Free Survival (PFS) | Arm II (Trebananib and Anti-VEGF Therapy) | 5.2 | 95% Confidence Interval 2.7 to 10.8 | months | |
| Number of Participants With Grade 3, 4, 5 Toxicities Related to the Treatment Drugs | Arm I (Trebananib Monotherapy) | SAE Cardiac disorders: Cardiac arrest | 0 | Participants | |
| Number of Participants With Grade 3, 4, 5 Toxicities Related to the Treatment Drugs | Arm II (Trebananib and Anti-VEGF Therapy) | SAE Cardiac disorders: Cardiac arrest | 1 | Participants | |
| Number of Participants With Grade 3, 4, 5 Toxicities Related to the Treatment Drugs | Arm I (Trebananib Monotherapy) | SAE Metabolism and nutrition disorders: Hypokalemia | 1 | Participants | |
| Number of Participants With Grade 3, 4, 5 Toxicities Related to the Treatment Drugs | Arm II (Trebananib and Anti-VEGF Therapy) | SAE Metabolism and nutrition disorders: Hypokalemia | 0 | Participants | |
| Number of Participants With Grade 3, 4, 5 Toxicities Related to the Treatment Drugs | Arm I (Trebananib Monotherapy) | SAE Respiratory, thoracic and mediastinal disorders: Dyspnea | 1 | Participants | |
| Number of Participants With Grade 3, 4, 5 Toxicities Related to the Treatment Drugs | Arm II (Trebananib and Anti-VEGF Therapy) | SAE Respiratory, thoracic and mediastinal disorders: Dyspnea | 1 | Participants | |
| Number of Participants With Grade 3, 4, 5 Toxicities Related to the Treatment Drugs | Arm I (Trebananib Monotherapy) | SAE Respiratory, thoracic and mediastinal disorders: Pleural effusion | 1 | Participants | |
| Number of Participants With Grade 3, 4, 5 Toxicities Related to the Treatment Drugs | Arm II (Trebananib and Anti-VEGF Therapy) | SAE Respiratory, thoracic and mediastinal disorders: Pleural effusion | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01664182/results